Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals

References

• Tidwell R, Boykin D. Dicationic DNA minor groove binders as antimicrobial Agents. In: Small Molecule DNA and RNA Binders. Demeunynck M (Ed.). John Wiley & Sons, NJ, USA 414–460 (2004).
   Google Scholar
• Soeiro MN, De Souza EM, Stephens CE, Boykin DW. Aromatic diamidines as antiparasitic agents. Exp. Opin. Investig. Drugs14(8), 957–972 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis.30(Suppl. 1), S5–S14 (2000).
   PubMed Web of Science ®Google Scholar
• Miller RF, Allen E, Copas A, Singer M, Edwards SG. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax61(8), 716–721 (2006).
   PubMed Web of Science ®Google Scholar
• Huang L, Hecht FM. Why does Pneumocystis carinii pneumonia still occur? AIDS14(16), 2611–2612 (2000).
   PubMed Web of Science ®Google Scholar
• Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS14(16), 2559–2566 (2000).
   PubMed Web of Science ®Google Scholar
• Morris A, Lundgren JD, Masur H et al. Current epidemiology of Pneumocystis pneumonia. Emerging Infect. Dis.10(10), 1713–1720 (2004).
   PubMed Web of Science ®Google Scholar
• Benson CA, Kaplan JE, Masur H et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm. Rep.53(RR-15), 1–112 (2004).
   PubMedGoogle Scholar
• Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N. Engl. J. Med.350(24), 2487–2498 (2004).
   PubMed Web of Science ®Google Scholar
• Barry S, Johnson M. Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management. HIV Med.2(2), 123–132 (2001).
   PubMedGoogle Scholar
• Safrin, S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J. Infect. Dis.170(4), 912–917 (1994).
   PubMed Web of Science ®Google Scholar
• Klein NC, Duncanson FP, Lenox TH et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS6(3), 301–305 (1992).
   PubMed Web of Science ®Google Scholar
• Huang L, Crothers K, Atzori C et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerging Infect. Dis.10(10), 1721–1728 (2004).
   PubMed Web of Science ®Google Scholar
• Wharton JM, Coleman DL, Wofsy CB et al. Trimethoprim–sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann. Intern. Med.105(1), 37–44 (1986).
   PubMed Web of Science ®Google Scholar
• Toma E, Thorne A, Singer J et al. Clindamycin with primaquine vs. trimethoprim–sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin. Infect. Dis.27(3), 524–530 (1998).
   PubMed Web of Science ®Google Scholar
• Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS: a double-blind, randomized trial of oral trimethoprim–sulfamethoxazole, dapsone–trimethoprim, and clindamycin–primaquine. Ann. Intern. Med.124(90) 792–802 (1996).
   PubMed Web of Science ®Google Scholar
• Sattler FR, Frame P, Davis R et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J. Infect. Dis.170(1), 165–172 (1994).
   PubMed Web of Science ®Google Scholar
• Hughes W, Leoung G, Kramer F et al. Comparison of atovaquone (566C80) with trimethoprim–sulfamethoxazole to treat pneumocystis carinii pneumonia in patients with AIDS. N. Engl. J. Med.328(21), 1521–1527 (1993).
   PubMed Web of Science ®Google Scholar
• Midgley I, Fitzpatrick K, Taylor LM et al. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride). Drug Metab. Dispos.35(6), 955–967 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou L, Lee K, Thakker DR, Boykin DW, Tidwell RR, Hall JE. Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across caco-2 cell monolayers via its methylamidoxime prodrug. Pharm. Res.19(11), 1689–1695 (2002).
   PubMed Web of Science ®Google Scholar
• Hildebrandt E, Boykin DW, Kumar A, Tidwell RR, Dykstra CC. Identification and characterization of an endo/exonuclease in Pneumocystis carinii that is inhibited by dicationic diarylfurans with efficacy against Pneumocystis pneumonia. J. Eukaryot. Microbiol.45(1), 112–121 (1998).
   PubMed Web of Science ®Google Scholar
• Turner PR, Denny WA. The mutagenic properties of DNA minor-groove binding ligands. Mutat. Res.355(1–2), 141–169 (1996).
   PubMed Web of Science ®Google Scholar
• Connor TH. Trizna Z. Pentamidine isethionate is negative in tests for microbial mutagenicity and chromosomal breakage in vitro. Toxicol. Lett.63(1), 69–74 (1993).
   Web of Science ®Google Scholar
• Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cervisiae. Antimicrob. Agents Chemother.48(10), 3968–3974 (2004).
   PubMed Web of Science ®Google Scholar
• Lanteri CA, Stewart ML, Brock JM et al. Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance. Mol. Pharmacol.70(5), 1585–1592 (2006).
   PubMed Web of Science ®Google Scholar
• Saulter JY, Kurian JR, Trepanier LA et al. Unusual dehydroxylation of antimicrobial amidoxiime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab. Dispos.33(12), 1886–1893 (2005).
   PubMed Web of Science ®Google Scholar
• Wang MZ, Saulter JY, Etsuko Usuki et al. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab. Dispos.34(12), 1985–1994 (2006).
   PubMed Web of Science ®Google Scholar
• Tidwell RR, Jones SK, Naiman NA et al. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother.37(8), 1713–1716 (1993).
   PubMed Web of Science ®Google Scholar
• Boykin DW, Kumar A, Spychala J et al. Dicationic diarylfurans as anti-Pneumocystis carinii agents. J. Med. Chem.38(6), 912–916 (1995).
   PubMed Web of Science ®Google Scholar
• Boykin DW, Kumar A, Hall JE et al. Anti-pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg. Med. Chem. Lett.6(24), 3017–3020 (1996).
   Web of Science ®Google Scholar
• Yeramian P, Kruse M, Kecskes A et al. Safety and clinical pharmacokinetics of DB289, a new orally bioavailable dication. Presented at: 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA,16–19 December (2001) (Abstract F-2163).
   Google Scholar
• Yeramian P, Meshnick, Krudsood S et al. Efficacy of DB289 in Thai patients with Plasmosium vivax or acute, uncomplicated Plasmodium falciparum infections. J. Infect. Dis.192(2), 319–22 (2005).
   PubMed Web of Science ®Google Scholar
• Yeates C. DB-289 Immtech International. IDrugs6, 1086–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Blum J, Pizzagalli F, Thompson M et al. Efficacy and safety of DB289, a new oral drug for treatment of first stage sleeping sickness: preliminary results from Phase II trials. Presented at: Medicine and Health in the Tropics Meeting. Marseille, France, September 15 2005 (Abstract O-101).
   Google Scholar
• Yeramian P, Leon J, Huarcaya E et al. Efficacy and safety of DB289, a new oral drug for treatment of Pneumocystis jiroveci pneumonia in AIDS patients. Clin. Microbiol. Infect.11(5), 96 (2005) (Abstract O405).
   Google Scholar